Novartis injects street theatre into London Vet Show 2012
Man in a box and animal performers entertain veterinarians at the London Vet Show 2012
Novartis injected some theatre into this year’s London Vet Show surprising visitors with its man in a box and animal ‘street’ performers. The characters were raising awareness of the company’s non-steroidal anti-inflammatory drug, Onsior®. Veterinary surgeons were directed to the Novartis stand where they had the chance to win an iPad3.
A recent published clinical study demonstrated Onsior® Injection had superior efficacy to meloxicam injection in reducing post-operative pain in cats.1 More information can be found at www.onsior-relief.co.uk.
Note to editor
Onsior® is an effective, tissue-selective, non-steroidal anti-inflammatory drug that offers effective pain relief in cats and dogs. Onsior® solution for injection is recommended for the treatment of pain and inflammation associated with soft tissue surgery in cats and dogs, plus orthopaedic surgery in dogs. In tablet form, Onsior® is prescribed to treat pain and inflammation associated with musculo-skeletal disorders in cats and chronic osteoarthritis in dogs.
Full product information is available at www.onsior-relief.co.uk
The winner of the iPad3 will be chosen on Monday 19th November. To win the iPad3, delegates had to have their picture taken in the stand’s photobooth, upload their picture onto Facebook and tag the London Vet Show. The picture with the most ‘likes’ will be the winner.
About Novartis Animal Health
Novartis Animal Health researches, develops and commercializes leading animal treatments that meet the needs of pet owners, farmers and veterinarians. Headquartered in Basel, Switzerland and present in nearly 40 countries, Novartis Animal Health employs approximately 2,900 people worldwide. For more information, please visit www.ah.novartis.com or in the UK & IE visit www.farmanimalhealth.co.uk
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2011, the Group’s continuing operations achieved net sales of USD 58.6 billion, while approximately USD 9.6 billion (USD 9.2 billion excluding impairment and amortization charges) was invested in R&D throughout the Group. Novartis Group companies employ approximately 124,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com